<?xml version='1.0' encoding='utf-8'?>
<?xml-stylesheet type="text/xsl" href="/v2/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2026-10-12T18:13:06Z</responseDate>
  <request identifier="oai:figshare.com:article/33827336" metadataPrefix="oai_dc" verb="GetRecord">https://api.figshare.com/v2/oai</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:figshare.com:article/33827336</identifier>
        <datestamp>2026-09-16T04:21:28Z</datestamp>
        <setSpec>category_37339</setSpec>
        <setSpec>category_37363</setSpec>
        <setSpec>category_37366</setSpec>
        <setSpec>category_37375</setSpec>
        <setSpec>portal_1012</setSpec>
        <setSpec>item_type_3</setSpec>
        <setSpec>month_year_09_2026</setSpec>
      </header>
      <metadata>
        <oai_dc:dc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"  xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:title>Table 2 from A Phase Ib/II Study of Atezolizumab in Combination with Thiopurine Therapy in Patients with Metastatic Solid Tumors and Intermediate Tumor Mutational Burden</dc:title>
          <dc:creator>Christine Federspiel Secher (24960179)</dc:creator>
          <dc:creator>Martin Højgaard (17977695)</dc:creator>
          <dc:creator>Iben Spanggaard (24960182)</dc:creator>
          <dc:creator>Ane Yde Schmidt (24960185)</dc:creator>
          <dc:creator>Yuliu Guo (24960188)</dc:creator>
          <dc:creator>Luca Robinson (24960191)</dc:creator>
          <dc:creator>Daniela De Zio (24960194)</dc:creator>
          <dc:creator>Linea N. Toksvang (24960197)</dc:creator>
          <dc:creator>Frederik Otzen Bagger (15241825)</dc:creator>
          <dc:creator>Kjeld Schmiegelow (15083530)</dc:creator>
          <dc:creator>Kristoffer S. Rohrberg (18941584)</dc:creator>
          <dc:subject>Cancer</dc:subject>
          <dc:subject>Immuno-oncology</dc:subject>
          <dc:subject>Clinical Research and Trials</dc:subject>
          <dc:subject>Methods and Technology</dc:subject>
          <dc:subject>Clinical Trial Results</dc:subject>
          <dc:subject>Combination Immunotherapy</dc:subject>
          <dc:subject>Gene Technologies</dc:subject>
          <dc:subject>High-throughput sequencing</dc:subject>
          <dc:subject>Immunotherapy</dc:subject>
          <dc:subject>Precision Medicine</dc:subject>
          <dc:description>&lt;p&gt;Treatment-related AEs in all included patients.&lt;/p&gt;</dc:description>
          <dc:date>2026-09-16T00:00:00Z</dc:date>
          <dc:type>Dataset</dc:type>
          <dc:type>Dataset</dc:type>
          <dc:identifier>10.1158/2767-9764.33827336</dc:identifier>
          <dc:relation>https://figshare.com/articles/dataset/Table_2_from_A_Phase_Ib_II_Study_of_Atezolizumab_in_Combination_with_Thiopurine_Therapy_in_Patients_with_Metastatic_Solid_Tumors_and_Intermediate_Tumor_Mutational_Burden/33827336</dc:relation>
          <dc:rights>CC BY</dc:rights>
        </oai_dc:dc>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
